HOME- R&D
- Bryn Mawr Conference
- Hyderabad Conference
- Workshops & Training
- Program
- Drug Discovery Innovation
- Proteins
- Quantum Biochemistry
- Screening
- Web Services
- Abstracts
- Speakers
- Bender, A
- Bryant, S
- Coles, S
- Covell, D
- De Sousa, J
- Dimitropoulos, D
- Gasteiger, J
- Golovin, A
- Henrick, K
- Irwin, J
- Kel, A
- Krissinel, E
- Nicklaus, M
- Poroikov, V
- Rassokhin, D
- Schwede, T
- Pharmacophores
- Graph Mining
- Nanotech
- Membranes & Ion Channels
- Exhibition
- Registration
- Jobs
- Contact
- Schedule
|
|
|
|
|
|
|
| Dr. Covell received his Ph.D. in Bioengineering (1980) from the University of Michigan. His previous academic degrees, also obtained at the same institution were in Aerospace Engineering (BSE, 1971, cumlaude), Computer Science (M.S.E., 1975), and Biomedical Engineering (M.S.E., 1975). Following a one year postdoctoral project funded by the American Diabetes Foundation, Dr. Covell joined the Laboratory of Mathematical Biology and the National Cancer Institute in the NIH. Over the next few years he developed a series of computational models of pharmacokinetic and physiologic systems important in the understanding of various disease states. In 1990 Dr. Covell became a Senior Investigator in the Screening Technologies Branch of the National Cancer Institute, where he heads up a research team of scientists focused on the development of informatic-based tools for the discovery of novel treatments of cancer. This research program is broadly based on the screening, genetic and testing data that has been generated in the NCI over the past 3 decades. The primary research focus is the development of a search-and-query information system for the study and discovery of novel agents in the treatment of cancer.
|
|
Search-and-query Information System for the Study and Discovery of Novel Agents in the Treatment of Cancer
David Covell, National Cancer Institute, Building 1052, Rm 236, Frederick, MD 21702-1201, USA
The National Cancer Institute has maintained a panel of immortalized tumor cell lines since 1990 for the purpose of screening chemical agents as candidates in the search for more effective cancer treatments. During these past 25 years nearly 80,000 small synthetic compounds and an equal number of natural product extracts have been assayed in the NCI's tumor screen. In parallel with this screening effort, the NCI has maintained a follow-up protocol comprised of secondary testing of active compounds in hollow-fiber and xenograft models. Parallel measurements of gene expressions within the NCI's tumor cell panel have complemented this data as well as the development of nearly a dozen molecular target assays screened against a panel of ~200,000 small molecules. The data generated in these screens has been the subject of efforts to devise informatic-based methods for data mining. The product of this effort is embodied within the publicly accessible web tool at the url 'spheroid.ncifcrf.gov'. The utilities within this web site represent a search-and-query information system for the study and discovery of novel agents in the treatment of cancer. The functionalities within this web utility allow interactions with a wide range of public databases and the NCI's screening data. Presentation and discussion of these utilities will be made in the context of recent drug discovery explorations.
|
|
|
|
|
|
|
|
|
